Palonosetron

Form: IV Injection

Strength: 0.25 mg/5 mL (0.05 mg/mL)

Reference Brands: Aloxi® (US & EU)

Category: Oncology Cancer Care

Palonosetron Injection is a next-generation 5-HT3 receptor antagonist used to prevent chemotherapy-induced and post-operative nausea and vomiting (CINV & PONV). Known for its long half-life and superior efficacy, Palonosetron provides extended protection against both acute and delayed emesis. It is available in 0.25 mg/5 mL and 0.075 mg/mL IV formulations, ideal for hospital and oncology settings. Marketed under Aloxi® in the US and EU, and also offered in generic form, it is manufactured under GMP-certified conditions. Palonosetron is a preferred antiemetic for pharmaceutical distributors seeking reliable oncology support across Europe and North America.